Guilin Sanjin Of China Seeks To Be First To Try IPO In Nine Months
This article was originally published in PharmAsia News
China's Guilin Sanjin Pharmaceutical is busy promoting itself to potential institutional investors as it attempts to be the nation's first company to go public in nine months. Guilin Sanjin is launching an initial public offering, now free to do so after regulators lifted a freeze on IPOs as of June 18. The medium-size drug maker seeks to raise nearly $93 million by going public. (Click here for more
You may also be interested in...
Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.
Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC
The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.
Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.